Sat, Sep 20, 2014, 2:13 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Seattle Genetics Inc. Message Board

mauihope1969 14 posts  |  Last Activity: Sep 5, 2014 11:22 AM Member since: Mar 10, 2014
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • mauihope1969 mauihope1969 Sep 5, 2014 11:22 AM Flag

    I think he gave his reasons at the time. He had made the lion's share of possible gain there. Probably there is more concern of how the temporary shut down of the Sugar Land refinery will impact earnings and dividend this Q. Normally that would equate to about a buck in earnings. Really good news is that it should do great in q4 as the Brent/WTI spread widens...now in the $8 range. Yet unknown is the impact of the Atlantic City melt-down onTropicana. Will it drive more business to the remaining casinos or drive tourists elsewhere? I think they should market the Trop. Express Laughlin to Del Web based on cliental. The first 55 plus resort?

  • Reply to

    Price Range Here is $17 to $19 -Range of 12%

    by barebuttbob2015 Aug 27, 2014 12:16 PM
    mauihope1969 mauihope1969 Sep 1, 2014 11:14 AM Flag

    It's not nearly so bad. In fact NFJ has performed in line with the S&P 500 over the last 8 years.
    NFJ has paid out $14.13 in those eight years. The current price is $19.13. That is $33.26 on your $22.50 investment or about a 45% return. The S&P 500 peaked at $130 in '06 when you bought NFJ. It's now $200 (50%) higher. That excludes the S&P's dividend in the 2% range. Had you reinvested the NFJ dividend you would have outperformed. So all in all...not bad.

    If ever there was a time to be cautious I think it is now. The discount has been distributed. The asset values are stretched as investors have reached for yield and it is beginning to sell at a premium to those stretched values.

  • Reply to

    Possible to pick more shares up at $100?

    by margate1980 Aug 6, 2014 11:57 AM
    mauihope1969 mauihope1969 Aug 6, 2014 12:51 PM Flag

    Could sell the Sept $100 put. It would either get you in closer to $97 or give you the $2.75 or $3.
    I've sold some $100s.

    Sentiment: Buy

  • Reply to

    Still pretty low volume, buy while you can.

    by margate1980 Aug 5, 2014 10:46 AM
    mauihope1969 mauihope1969 Aug 6, 2014 1:17 AM Flag

    Good Q2 #s. It's not a stretch extrapolating it over the next year as the economy gathers momentum or $16 per share earnings. Even reducing the next 3 Qs by 25% gets us to $13.
    $13 X a low PE of 13 gets us to north of $150 share price.
    I don't see too many analysts rushing to cover this. Maybe to many moving parts to estimate.
    I can't invest smarter than Icahn and company so why try.
    I'm in.

  • Reply to

    Compare results DLBCL

    by mauihope1969 Jul 15, 2014 6:23 PM
    mauihope1969 mauihope1969 Jul 17, 2014 11:13 PM Flag

    Thanks for your views Kool. Contrary to what you may think I'm one of SGEN's biggest fans.

  • Reply to

    Compare results DLBCL

    by mauihope1969 Jul 15, 2014 6:23 PM
    mauihope1969 mauihope1969 Jul 17, 2014 8:13 PM Flag

    Thanks for pointing out my obvious error in typing SGN33a instead of SGNCD19 on my last post. I hope that most investors here knew what I meant.

    The relapse DLBCL market is one of the larger. About 30% relapse(aprox.20000). All the drugs I've mentioned are at about the same point in development-phase 1. All compete for the same patient population. If approved, how well they perform will ultimately determine what kind of revenue they can generate. CARTs have as much or more history than ADCs. First to market will have an advantage.
    JUNO is overcoming the CRS problem with daily monitoring. The short term reaction to the initial infusion is far less than the long-term toxicity experienced by patients receiving traditional chemo.
    Data as it stands favors the CARTs.
    All this is years away but potential as been priced in here. If the future outlook changes so should current price.

  • Reply to

    Compare results DLBCL

    by mauihope1969 Jul 15, 2014 6:23 PM
    mauihope1969 mauihope1969 Jul 15, 2014 6:40 PM Flag

    IMGN results are Phase 2 SAR3419. SGEN is early Phase 1 and will improve. They are both ADCs.
    Data consistently shows CAR-Ts out performing. Juno and Novartis have not yet released their DLBCL. I suspect it will be in line with KITE's. JUNO seems to have a handle on the toxicity. SGN33a and SAR3419 are in a different class.
    SGN33a looks to be on track for approval. Maybe fast-tract. This level of competition will affect the market.

  • mauihope1969 by mauihope1969 Jul 15, 2014 6:23 PM Flag

    KITE PHARMA went public a few weeks ago with about a $130ml IPO and became the latest company to go after the crowded CD19 space. Juno and PennSt/Novartis have released some early results for leukemia(ALL) along with SGEN. NOW some DLBCL results.
    Gotta take Stifel's word on these data for KITE:
    "We see the 80% objective response rate (ORR) and 60% complete response (CR) rate that KTE-C19 has generated in early testing in DLBCL as strongly outperforming current standard of care's 43% objective response rate. As we expect KTE-C19 to require only a single administration, we believe that Kite can justify a $200,000 price for the drug, which we estimate will lead to a profit despite our high $55,000 cost of production estimate.”
    IMGN:
    "The ORR was 53.8% among the patients with relapsed disease, with 69.2% having stable disease or better. The 14 patients with objective responses included 5 patients with complete responses (CRs) and 9 patients with partial responses (PRs).
    Among the 15 patients with disease refractory to the last treatment, the ORR was 26.7%, with 46.7% having stable disease or better. These included 1 CR and 3 PRs.
    The 55 efficacy evaluable patients also included 14 individuals with primary refractory disease. Among these patients, the ORR was 21.4%, with 35.7% having stable disease or better. The objective responses reported included 1 CR as well as 2 PRs."
    SGEN:
    "At the time of data analysis, of the 37 patients treated across all dose levels, the objective response rate observed was 30 percent (11 patients). Six patients (16 percent) achieved a complete remission, five (14 percent) achieved a partial remission, 13 (35 percent) had stable disease and 13 (35 percent) had progressive disease as best response. The clinical trial is ongoing with nine of the 37 patients (24 percent) remaining on treatment and new patients continuing to be enrolled."

  • Reply to

    CC on July 31

    by terryramsey007 Jul 14, 2014 2:54 PM
    mauihope1969 mauihope1969 Jul 15, 2014 11:53 AM Flag

    The only "they" that already know are insiders....AKA Baker Bro. They are buyers.
    Today's sell-off is more indiscriminate selling that will, like Silver says, create a buying opportunity. Hopefully.

  • Reply to

    CC on July 31

    by terryramsey007 Jul 14, 2014 2:54 PM
    mauihope1969 mauihope1969 Jul 14, 2014 11:07 PM Flag

    News on SGN33a should be coming soon. It's gone longer than the first CD19 read. It will give us a glimpse of a "next generation ADC". AML is a tough target. Good news there will be well received and could lead to new PBD collaborations. The CD33 target is wide open. No Immunological competition with that target save for maybe one in China.
    Of course the best news would be that they have been successful with the FDA in redesigning Echelon
    1 & 2. I think it will happen but not yet.
    They will beat estimates.

    Sentiment: Hold

  • Reply to

    So, How large is post-transplant ?

    by mauihope1969 Jul 9, 2014 7:32 PM
    mauihope1969 mauihope1969 Jul 9, 2014 9:40 PM Flag

    The post-transplant patients who have received Adcetris have a much smaller incidence of relapse and are living longer. In fact, unfortunately, data will understate the benefits because many patients will outlive the end of the trial.
    Technically, now nearly all relapse patients have access with the current approved indications, both pre-transplant and post-transplant. That number is only 1800 or so per year. SGEN enjoys an excellent 70% market penetration in this group. The vast majority of HL patients (80%+) are cured by today's frontline treatments and do not relapse. To reach the 50%+ you talking about Adcetris will have to excel at frontline. Till that happens, sales and revenue will be on hold.

  • The Aethera trial has been very successful at extending post-transplant relapse. Perhaps a cure for many. Results may be released late 2014.
    Because the trial was required as a condition of approval it does not automatically expand the label. Undoubtedly SGEN will use data from the trial to apply for the extension ASAP and I believe they have expressed that intention.
    So how big is it in terms of revenue?
    A 2013 ASCO abstract calculated that there were 790 HL transplants per year and that relapse occur in approximately 44%. Aethera has proved Adcetris can cut that number significantly and give instead hope for a cure.
    I believe that presently the relapsed 44% have access under the current label so this adds 300-400 potential patients or about a $30-$40mil potential US market. I can't imagine many Docs not ordering it for a transplant patient so I believe market penetration will be close to 100%. Three or four hundred may not sound like much but that is in the 20-25% growth range. Currently the 2015 analysts revenue estimates look right to me.
    All just a guess. Do your own DD.

  • Reply to

    UBS Upgrade of SGEN To Buy Today With PT of $48

    by ricardouno Jul 9, 2014 7:15 AM
    mauihope1969 mauihope1969 Jul 9, 2014 4:15 PM Flag

    Love the company but share price is a function of the market.
    To be fair I meant sales of 40 million. and here is their words on Echelon.
    "The primary endpoint in the ECHELON-1 and ECHELON-2 trials is progression-free survival per independent review facility assessment in patients treated with ADCETRIS compared to that achieved with therapy in the control arm. Given encouraging PFS trends in our phase 1 data combining ADCETRIS with standard chemotherapy regimens and the slower- than-anticipated events in the AETHERA trial, we and Takeda are evaluating the potential that event rates may be slower than expected in both the ECHELON-1 and ECHELON-2 trials and plan to work with appropriate regulatory agencies on any proposed trial modifications."

  • Reply to

    UBS Upgrade of SGEN To Buy Today With PT of $48

    by ricardouno Jul 9, 2014 7:15 AM
    mauihope1969 mauihope1969 Jul 9, 2014 1:04 PM Flag

    This upgrade follows an upgrade to buy from hold by Zachs yesterday..
    Still too early for me to get back in. I think we are about to see act-2 of the biotech sell off and a better entry point. This touched the 200day resistance and backed off. Short interest is up 1mil shares now.
    Earnings have rarely been a high point here. Maybe we'll see a slight uptick on rev to around $40 in Adcetris sales. No collaboration deals since the AbbVie deal in Q1. I think that translates to another $20-$25mil cash burn. Money seems to be flowing toward immune-oncology now not ADC's. Aethera is not a label expansion trial and they've said Exhelon's event based trial is taken longer than planned. I 'm thinking it may be 2017 now. So it will try investor patience. My guess is we see Cantor Fitzgerald's high $20 target this year.

    Sentiment: Hold

SGEN
40.60-0.55(-1.34%)Sep 19 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.